Pregnancy RSV vaccine slashes newborn hospital admissions by over 80%

A vaccine given during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.

How the vaccine protects vulnerable infants

RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can vary from causing mild, cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most severe cases, the inflammation in the lungs becomes life-threatening, with small numbers of infants dying from the infection annually. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”

The pregnancy vaccine works by stimulating the mother’s immune system to generate protective antibodies, which are then transferred to the developing baby through the placenta. This mother-derived protection provides newborns with immediate protection from the point of delivery, precisely when they are most vulnerable to RSV. The latest research shows that protection reaches approximately 85% when the vaccine is administered four weeks or more before delivery. Even shorter intervals between vaccination and birth can still provide substantial defence, with evidence suggesting that a fortnight’s interval is sufficient to shield babies delivered prematurely. Dr Watson advises pregnant women to receive the vaccine on schedule, whilst noting that protection remains possible even if administered later in the third trimester.

• Nearly 85 per cent protection when immunised four weeks before birth
• Antibodies from the mother passed through the placenta protect newborns from day one
• Protection possible with 2-week gap before early delivery
• Vaccination in the third trimester still provides meaningful infant protection

Strong evidence from the latest research

The efficacy of the pregnancy RSV vaccine has been confirmed through a thorough investigation carried out throughout England, analysing data from approximately 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90 per cent of all births during that six-month period, providing comprehensive and reliable information of the vaccine’s real-world impact. The study’s conclusions have been validated by the UK Health Security Agency as showing “excellent protection” for newborns during their earliest and most vulnerable period. The scale of this research provides healthcare professionals and parents-to-be with assurance in the vaccine’s established performance across varied populations and settings.

The results present a striking picture of the vaccine’s protective power. More than 4,500 babies were hospitalised with RSV throughout the study period, with the vast majority being infants whose mothers did not receive the vaccination. This marked difference underscores the vaccine’s vital importance in protecting against serious illness in newborns. The drop in hospital admissions above 80 per cent represents a significant public health achievement, helping to prevent thousands of infants from experiencing the distressing and potentially serious symptoms connected with severe RSV infection. These findings support the importance of the vaccination programme established in the UK in 2024.

Study design and parameters

The research analysed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify clear comparisons of RSV infection rates and hospitalisations. The sizeable sample and comprehensive nature of the data gathering ensured that findings were statistically robust and reflective of the wider population, rather than isolated cases or small subgroups.

The study specifically recorded hospital admissions for RSV among infants born to mothers who had been given the vaccine at different timepoints before delivery. This allowed researchers to establish the shortest interval needed between vaccination and birth for optimal protection, as well as to determine whether protection stayed significant with briefer timeframes. The methodology measured practical outcomes rather than controlled laboratory conditions, providing tangible evidence of how the vaccine functions when delivered across varied healthcare environments and patient circumstances throughout the third trimester of pregnancy.

Grasping RSV and the risks

Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospitalisation in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their early months of life, with severity changing substantially from mild cold-like symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during peak seasons.

The infection produces deep inflammation in the lungs and airways, making it dangerously difficult for infected babies to breathe and feed effectively. Parents commonly see their babies visibly struggling, their chests rising whilst they try to pull adequate oxygen into their compromised lungs. Whilst most infants recover with palliative treatment, a small but significant proportion perish from RSV complications each year, making immunisation programmes a vital health service priority for protecting the most vulnerable and youngest members of society.

• RSV causes inflammation in lungs, resulting in serious respiratory problems in babies
• Nearly 50% of infants acquire the infection in their first few months of life
• Symptoms vary between minor cold-like symptoms to life-threatening chest infections needing hospital treatment
• Over 20,000 UK babies require serious hospital care for RSV each year
• Few babies die from RSV related complications each year in the UK

Uptake rates and specialist advice

Since the RSV vaccine programme began in 2024, health officials have emphasised the value of pregnant women receiving their jab at the ideal time for greatest protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has stressed that the timing is essential for guaranteeing newborns receive the maximum immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery delivers nearly 85% protection, experts advise women to receive their vaccine as soon as feasible from 28 weeks of pregnancy onwards to increase the antibodies passed to their babies through the placenta.

The communication from public health bodies remains clear: pregnant women ought to prioritise getting vaccinated during their third trimester, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has reassured pregnant women that protection is still achievable with shorter intervals between immunisation and delivery, including even a fourteen-day window for those delivering slightly early. This adaptable strategy acknowledges the practical demands of pregnancy whilst ensuring strong safeguarding for vulnerable newborns during their most critical early months when RSV poses the greatest risk of serious illness.

Regional differences in vaccination

Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have differed across different regions and NHS trusts. Some areas have achieved greater immunisation rates among eligible pregnant women, whilst others remain focused to boost understanding and access to the jab. These regional differences demonstrate differences across medical facilities, communication strategies, and community involvement initiatives, though the overall statistics shows consistently strong protection regardless of geographical location.

• NHS trusts rolling out multiple messaging strategies to engage with expectant mothers
• Regional disparities in immunisation take-up across England necessitate strategic intervention
• Local healthcare systems adapting programmes to suit specific population needs

Real-world impact and parent viewpoints

The vaccine’s remarkable effectiveness translates into tangible benefits for families across the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV before the launch of this preventative solution, the 80% drop in admissions equates to thousands of infants spared from serious illness. Parents no longer face the distressing scenario of seeing their babies labour to breathe or struggle to eat, symptoms that define critical RSV illness. The vaccine has fundamentally shifted the picture of neonatal lung health, offering expectant mothers a preventative option to safeguard their youngest infants during those crucial first weeks.

For families like that of Malachi, whose acute RSV infection led to devastating brain damage, the vaccine’s availability carries profound emotional significance. His mother’s promotion of the jab highlights the transformative consequences that treatable infection can have on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates strongly with parents now given protection. The knowledge that such significant complications—hospital admission, oxygen dependency, neurological damage—are now largely preventable has given considerable reassurance to expectant mothers during their late pregnancy, converting what was once an inevitable seasonal threat into a controllable health concern.